ClinicalTrials.gg
Not yet recruitingNCT05698303Updated Jan 26, 2023

A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

A Phase 1 interventional study of Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A) in Multiple Myeloma, sponsored by Nanjing IASO Biotechnology Co., Ltd.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Nanjing IASO Biotechnology Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,168 studies in Multiple Myeloma with a site in United States — 275 open to participants now, 503 under way, 66 of them phase 3. Multiple Myeloma · United States.

Planned enrollment
1,525th of 1,901
12 · median 36
Started
2023
with 83 others
Phase 1
559 of 2,168
64 open now
Primary completion
2024-05
later than 56 of 499 live
Registered
1,885th of 2,168
by date

Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 1,525th largest by planned enrollment of the 1,901 interventional ones that give a count, is one of 84 that started in 2023, is one of 559 in phase 1, reaches primary completion later than 56 of the 499 other live ones, and was the 1,885th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

275 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

270 more — sign in →

All 275 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,168 studies in Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

It is a dose expansion, open-label, phase Ib study to evaluate the safety, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of CT103A in patients with relapsed/refractory multiple myeloma.

Read the detailed description

A total of at least 12 subjects are planned to be enrolled in this study. Each subject will proceed through the following study periods:

  • Screening
  • Leukapheresis
  • Bridging therapy (at the discretion of the investigator)
  • Pre-lymphodepletion assessment
  • Lymphodepleting chemotherapy
  • Pre-infusion Assessment
  • CT103A infusion (Day 0)
  • 28-Day safety evaluation period
  • Post-treatment follow-up period (Day 29 through year 2)

All the subjects will be followed for safety and efficacy until disease progression, initiation of subsequent anti-myeloma therapy, withdrawal, death, loss to follow-up, study completion, end of study, or study termination, whichever occurs first. Subjects except those that are deceased, lost to follow-up, or have withdrawn their ICF will enter the long-term follow-up (LTFU) under a separate protocol for at least 15 years.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • relapsed/refractory multiple myeloma
  • RRMM
  • CAR-T
  • BCMA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age.
  2. Documented diagnosed with multiple myeloma according to the IMWG diagnostic criteria.
  3. Have received at least 3 , including a proteasome inhibitor, an immunomodulator-based chemotherapy, and an anti-CD38 therapy (prior exposure can be from different monotherapy or combination regimens), or are to both a proteasome inhibitor and an immunomodulatory agent (i.e., double refractory).
  4. Documented disease progression during or within 12 months of the most recent anti-myeloma treatment (except for subjects who received CAR-T as last-line therapy).
  5. For subjects with previous BCMA-targeted therapy, the best response should be at least PR, and positive BCMA expression on tumor cells by immunohistochemistry (IHC) or flow cytometry is required before enrollment.
  6. The presence of according to IMWG 2016 criteria at screening as determined by any of the following criteria:

    • Serum M-protein level ≥1.0 g/dL or urine M protein level ≥ 200 mg/24 h; or
    • Light chain multiple myeloma without measurable lesions in serum or urine: Involved serum free light chain ≥ 10 mg/dL and abnormal serum κ/λ free light chain ratio.
  7. score of 0 or 1 (refer to Appendix 2)
  8. Subjects must have appropriate organ function and meet all the following laboratory test results prior to enrollment:

    • Hematology: (ANC) ≥ 1×109/L (supportive growth factor is permitted, but must be without supportive treatment within 7 days before the laboratory test); absolute lymphocyte count (ALC) ≥0.3×109/L; count ≥50×109/L (must be without supportive blood transfusion within 7 days before the laboratory test); ≥80 g/L (without transfusion of red blood cells [RBC] within 7 days before the laboratory test; the use of recombinant human erythropoietin is permitted).
    • Liver function: (ALT) and aspartate transaminase (AST) ≤ 2.5× (ULN); serum total ≤ 1.5×ULN except with known Gilbert's syndrome who have serum bilirubin ≤ 3×ULN.
    • Renal function: (CrCl) calculated using the Cockcroft-Gault formula ≥ 40 ml/min.
    • Coagulation function: Fibrinogen ≥1.0 g/L; ≤1.5× ULN, prothrombin time (PT) ≤1.5× ULN.
    • Corrected serum calcium ≤11 mg/dL
    • Oxygen saturation (by Fingertip Pulse Oximeter) ≥92%.
    • (LVEF) ≥45%.
  9. Female subjects of or male subjects with a partner of childbearing potential agree to use effective methods from screening and continued during study treatment until one year after the last dose.
  10. The subject must personally sign an form approved by the ethics committee in writing.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with (GVHD) or those requiring long-term use of .
  2. Received hematopoietic stem cell transplant (Auto-HSCT) within 12 weeks before apheresis or received prior allogeneic hematopoietic stem cell transplant (Allo-HSCT).
  3. Received prior anti-myeloma therapies as follows:

    • Treatment with monoclonal antibodies within 21 days prior to apheresis, or
    • Treatment with cytotoxic chemotherapy or proteasome inhibitor within 14 days prior to apheresis, or
    • Treatment with immunomodulator within 7 days prior to apheresis, or
    • Anti-myeloma therapies other than those described above within 14 days or at least 5 half-lives (whichever is shorter) prior to apheresis.
  4. Use of (defined as prednisone or equivalent > 20 mg/day) at a therapeutic dose within 7 days prior to apheresis. Physiologic replacement, topical, and inhalation steroids are permitted, nevertheless.
  5. Severe heart disease: Including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive cardiac failure ( [NYHA] classification grade ≥ III), severe arrhythmia.
  6. Unstable systemic diseases judged by the investigator: Including but not limited to severe liver, kidney or metabolic diseases requiring therapy.
  7. other than multiple myeloma within 5 years prior to screening, excluding adequately treated carcinoma in situ of cervix, basal or squamous epithelial cell skin cancer, localized prostate cancer post radical operation, ductal carcinoma in situ of the breast post radical operation.
  8. History of organ transplant.
  9. Suspected or confirmed central nervous system involvement.
  10. Plasma cell leukemia at the time of screening (>2.0×109/L plasma cells by standard differential), Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary AL amyloidosis.
  11. Major surgery within 2 weeks prior to apheresis, or planned surgery within 2 weeks after study treatment administration (subjects who plan to receive surgery under local anesthesia are permitted to be enrolled in this study).
  12. Treated with other interventional clinical products within 1 month before signing the form (ICF).
  13. Evidence of serious active viral, bacterial, or uncontrolled systemic fungal infection prior to apheresis.
  14. Positive surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with detectable hepatitis B virus (HBV) DNA in peripheral blood; positive virus (HCV) antibody with positive HCV RNA in peripheral blood; positive (HIV) antibody; positive cytomegalovirus (CMV) DNA; positive syphilis test.
  15. Pregnant or breastfeeding women or planning to become pregnant while enrolled in this study or within 1 year after receiving study treatment.
  16. Stroke, seizure or psychosis within 6 months of signing ICF.
  17. Non-hematological toxicities from previous anti-myeloma therapy have not recovered to baseline or grade ≤1 ( v5.0, except for alopecia and grade 2 peripheral neuropathy).
  18. Any issue that would impair the ability of the subject to receive or tolerate the planned treatment, to understand informed consent or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    CT103A in patients with RRMM

    After lymphodepletion, CT103A will be administered as a single infusion.

    Drug: Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)

Interventions

  • CT103A is an BCMA targeted genetically modified autologous T cell immunotherapy product that identifies and eliminates BCMA-expressing malignant and normal cells. CAR specifically recognizes BCMA with a low-immunogenic fully human single chain fragment variable (scFv), promotes CAR-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain, and enhances CAR-T proliferation and persistence through co-stimulatory signaling via 4-1BB.

    Also known as: CT103A

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events

    An assessment of severity grade will be made according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0, with the exception of cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS).

    Time frame: Up to 2 years after CT103A infusion.

  2. Incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)

    CRS and ICANS will be evaluated according to the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading.

    Time frame: Up to 2 years after CT103A infusion.

  3. Number of participants with laboratory abnormalities

    Number of participants with laboratory abnormalities will be reported.

    Time frame: Up to 2 years after CT103A infusion.

Secondary outcomes

  1. Overall response rate (ORR)

    The proportion of subjects who achieved at least a PR or better as defined by the International Myeloma Working Group (IMWG) response criteria.

    Time frame: Up to 2 years after CT103A infusion.

  2. Progression-free survival (PFS)

    Duration from the date of CT103A infusion to the date of first documented evidence of progressive disease or death due to any cause.

    Time frame: Up to 2 years after CT103A infusion.

  3. Overall survival (OS)

    Duration from the start of CT103A treatment to subject death (due to any cause).

    Time frame: Up to 2 years after CT103A infusion.

  4. Duration of response (DOR)

    Duration from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG criteria.

    Time frame: Up to 2 years after CT103A infusion.

  5. Time to response (TTR)

    Time interval from the date of CT103A infusion to the date of initial documentation of a response (PR or better)

    Time frame: Up to 2 years after CT103A infusion.

  6. Time to complete response (TTCR)

    Time interval from the date of CT103A infusion to the date of initial documentation of a complete response (CR) or stringent complete response (sCR).

    Time frame: Up to 2 years after CT103A infusion.

  7. MRD response assessment

    The proportion of subjects achieved MRD-negativity.

    Time frame: Up to 2 years after CT103A infusion.

  8. The duration of MRD-negativity

    The duration of MRD-negativity is defined as the time interval between the first occurrence of negative MRD after infusion and the first reversal of negative MRD results to positive.

    Time frame: Up to 2 years after CT103A infusion.

  9. CAR transgene level in peripheral blood.

    The CAR transgene level in peripheral blood both pre- and post- CT103A infusion will be measured and reported.

    Time frame: Up to 2 years after CT103A infusion.

  10. Soluble BCMA (sBCMA) in peripheral blood.

    The level of sBCMA in peripheral blood will be measured and reported.

    Time frame: Up to 2 years after CT103A infusion.

Other outcomes

  1. CAR-positive cell counts in peripheral blood.

    CAR-positive cell counts in peripheral blood will be measured and reported.

    Time frame: Up to 2 years after CT103A infusion.

  2. Presence of human anti-CAR antibodies

    The titer of confirmed positive anti-CAR antibodies in peripheral blood will be measured and reported.

    Time frame: Up to 2 years after CT103A infusion.

  3. Presence of RCL in peripheral blood.

    Presence of RCL in peripheral blood will be measured and reported.

    Time frame: Up to 2 years after CT103A infusion.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2023; primary completion for May 2024, 12 months later.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 12 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2022
First posted
Jan 26, 2023
StartEst.
May 8, 2023
Primary completionEst.
May 20, 2024
CompletionEst.
Jan 15, 2026
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05698303
Lead sponsor
Nanjing IASO Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Jan 26, 2023
Start date
May 8, 2023 (estimated)
Primary completion
May 20, 2024 (estimated)
Completion
Jan 15, 2026 (estimated)
Last update
Jan 26, 2023

Study contacts

Robert Z. Orlowski, M.D., Ph.D.
Contact
rorlowsk@mdanderson.org
713-792-2860
Oliver Kong, M.D.
Contact
Oliver.kong@iasobio.com
+86 13162113618
Nanjing IASO Biotherapeutics Co.,Ltd. Clinical trial
study director · Nanjing IASO Biotechnology Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Equecabtagene autoleucel

Start the discussion